Replies to post #190169 on Biotech Values

[onemodolar]

OCRX Please help.

OCRX continues to find support in the high 3s. The EV is simply too cheap for it to fall lower than that, IMO.

1.Do they have oral formulation in development? or ready to bring it to POC.

2. Other than no diarrhea, what would be clinical benefit compared to lactulose, Neomycin and Xifaxan ( about $1500/month) as a maintenance med.
Do we know any more info for post discharge oral formula?

3.With known efficacy/improvement of less than 23% Ocrx originally projected in O02, will one day shorter length of stay be enough to justify the use of 002 in acute setting?
Lactulose almost always bring ammonia level down soon or later for sure.